Marco Rizzardo (b. 1971) has been appointed Revenio's Vice President R&D, and a member of the Leadership Team. Rizzardo will start in his position no later than January 8, 2024. Marco Rizzardo will be responsible for the research and development of Revenio Group's ophthalmological devices and software solutions throughout their entire life cycle.

"During the past years, Revenio has gone through an evolution from a device supplier to a global leader in eye diagnostics solutions. I am very pleased to welcome a top talent like Marco Rizzardo to our team. Our product portfolio is competitive in terms of intraocular pressure measuring devices, retinal imaging devices, and retinal screening solutions utilizing AI. In addition, we continue to invest significantly in research and development to launch new products and solution innovations to the market. Marco has a significant role in driving our research and development activities forward in line with our strategy”, says Jouni Toijala, CEO of Revenio.

Marco Rizzardo has more than 20 years of experience in research and development of advanced medical technologies such as surgical robotics and digital solutions in leading roles of global companies. He has most recently worked as Technical Director in Alifax Srl, Italy and before that as Head of Medical Software in Cambridge Consultants Ltd, Great Britain.

“I am very excited to join Revenio and the opportunity to continue bringing innovative products and solutions to the market with Revenio’s talented team”, says Marco Rizzardo

As previously announced, Marco Rizzardo's predecessor, Giuliano Barbaro, who successfully led the R&D function, moved on to cancer research at the end of June 2023.

The resume of Marco Rizzardo is attached to this announcement.

More information
CEO Jouni Toijala, tel. +358 50 484 0085
jouni.toijala@revenio.fi

Distribution
Nasdaq Helsinki
FIN-FSA
Key media
www.reveniogroup.fi/en

Revenio Group in brief
Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand. iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for the diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care.

In 2022, the Group’s net sales totaled EUR 97.0 million, with an operating profit of EUR 29.7 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.